Cysteamine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Cysteamine
- Pharmacist Assessment Report
- Cysteamine: cystine-depleting aminothiol agent → mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cysteamine: cystine-depleting aminothiol agent → mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
One-Sentence Summary
Cysteamine is a cystine-depleting aminothiol agent that is currently marketed in Canada. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies. There are currently 0 clinical trials and 0 publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Cysteamine is known as a cystine-depleting agent with aminothiol (antioxidant) chemistry. It converts lysosomal cystine into a mixed disulfide that can leave the lysosome.
Mitochondrial oxidative phosphorylation disorders involve impaired cellular energy production, and redox stress is a common feature. A link between an aminothiol antioxidant and mitochondrial redox stress is therefore plausible. However, this is a hypothesis only: no trials or publications were compiled that study cysteamine in this disease, and the similarity to the original use has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02464705 | PROCYSBI | Not recorded | Not recorded |
| 02464713 | PROCYSBI | Not recorded | Not recorded |
| 02485605 | CYSTADROPS | Not recorded | Not recorded |
All three single-ingredient licences are currently valid.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9993), but no clinical trials or publications study cysteamine in this disease. The evidence level is therefore L5, and the mechanistic link remains speculative.
To proceed, the following is needed:
- Mechanism of action data for cysteamine
- Preclinical studies (e.g., cell or animal models of nuclear-DNA-related oxidative phosphorylation defects) testing cysteamine’s effect on mitochondrial redox stress
- Health Canada package insert warnings and contraindications, to allow safety screening
- Assessment of route and formulation compatibility with the target disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.